KRT18 and metabolic dysfunction-associated steatohepatitis: Similarly, CK18 showed an AUC of 0.79 in the development cohort to distinguish MASLD without steatohepatitis and MASH, which is in line with the pooled AUC of 0.70–0.87 to diagnose MASH found in a meta-analysis [34].